Analysis of Failure Time Data Arising from Studies with Alternating Treatment Schedules

Published in: Journal of the American Statistical Association, v.101, no. 474, 2006, p. 510-520

Posted on RAND.org on January 01, 2006

by Beth Ann Griffin, Stephen W. Lagakos

Read More

Access further information on this document at amstat.tandfonline.com

This article was published outside of RAND. The full text of the article can be found at the link above.

We develop statistical methods for designing and analyzing studies in which treatments are deliberately interrupted and reinitiated, but where interest lies in making inferences about continuous treatment use. We refer to such designs as alternating designs, because subjects alternate between periods in which they are taking the treatment of interest and periods when they are not. Our goals are to determine how to estimate the distribution of time to an event if the treatment were given continuously, to compare the distributions of two such continuously given treatments, and to assess the effects of covariates on the distribution of a continuously given treatment. We examine a nonparametric estimator of the cumulative hazard function for continuous treatment using data from an alternating design and show it to be uniformly consistent and asymptotically normal under certain conditions relating to the effects of interrupting the treatment. We then introduce nonparametric tests for comparing the distributions corresponding to two such continuously given treatments and derive their asymptotic properties under general alternatives to the null and under various conditions related to the interruption of treatment. We compare the properties of the alternating treatment design and the classical parallel group design and present results from a simulation study that assesses the size and power of the test procedures introduced. Finally, we examine partial likelihood methods for assessing the effects of covariates and continuous treatment on time until an event under a proportional hazards model. We illustrate the proposed methods using the results from a recent study in which subjects alternate between taking an active drug and placebo on an annual basis.

This report is part of the RAND Corporation External publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.

Our mission to help improve policy and decisionmaking through research and analysis is enabled through our core values of quality and objectivity and our unwavering commitment to the highest level of integrity and ethical behavior. To help ensure our research and analysis are rigorous, objective, and nonpartisan, we subject our research publications to a robust and exacting quality-assurance process; avoid both the appearance and reality of financial and other conflicts of interest through staff training, project screening, and a policy of mandatory disclosure; and pursue transparency in our research engagements through our commitment to the open publication of our research findings and recommendations, disclosure of the source of funding of published research, and policies to ensure intellectual independence. For more information, visit www.rand.org/about/principles.

The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.